Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Yet another question submitted to the shareholder forum

Since we are in a dispute with both TPL and Alliacense and PDS will not provide Alliacense with quarterly advances for MMP-related licensing expenses (10-Q, Note 6), how does the BoD expect that Alliacense will do ANY work to bring in licenses? When do you expect to resolve the differences with Alliacense in particular?

Share
New Message
Please login to post a reply